Core Insights - The company aims to achieve over 30 plasma collection stations and a plasma collection scale exceeding 1,000 tons during the 14th Five-Year Plan period [2] - As of now, the company has established a total of 21 plasma collection stations, including 4 under the Green Cross brand [2] - The raw plasma collection volume for the first half of 2025 reached 320.39 tons, representing a year-on-year growth of 7.2%, which is higher than the industry average growth rate [2]

Group 1 - The company announced a cash dividend distribution plan for the first half of 2025, proposing a payout of 1.50 yuan per 10 shares (including tax) [2] - The record date for the dividend distribution is set for September 25, 2025, while the ex-dividend date is September 26, 2025 [2]

证券代码：300294 证券简称：博雅生物 公告编号：2025-068 华润博雅生物制药集团股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、公司本次实施的利润分配方案为：以股份总数504,248,738股为基数，向 全体股东每10股派发现金红利1.500000元（含税）。公司本次现金分红的总金额 = 实 际 参 与 分 配 的 股 本 × 分 配 比 例 =504,248,738 股 ×1.500000 元 ÷10 股 =75,637,310.70元（含税）。 在实施权益分派的股权登记日前，如享有利润分配权的股份总额发生变动， 则以实施分配方案时股权登记日的享有利润分配权的股份总额为基数，按照分配 比例不变的原则对分配总额进行调整。 2、本次权益分派方案，按公司总股本折算每股现金分红=本次实际现金分红 总额/公司总股本=75,637,310.70/504,248,738=0.150000元。 3、本次权益分派实施后的除权除息参考价=除权除息前一交易日收盘价-按 公司总股本折算每股现金分红比例=除权除息 ...

北 京 大 成 律 师 事 务 所 关 于 的 法 律 意 见 书 www.dachenglaw.com 北京市朝阳区朝阳门南大街 10 号兆泰国际中心 B 座 16 层 16-21F, Tower B, Zhaotai International Center, 10 Chaoyangmen Nandajie, Chaoyang District, Beijing 100020, China Tel: 8610-58137799 Fax: 8610-58137733 法律意见书——博雅生物 2025 年第一次临时股东大会 华 润 博 雅 生 物 制 药 集 团 股 份 有 限 公 司 2025 年 第 一 次 临 时 股 东 大 会 北京大成律师事务所关于华润博雅生物制药集团股份有限 公司 2025 年第一次临时股东大会的法律意见书 致：华润博雅生物制药集团股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范 性文件的要求，北京大成律师 ...

特别提示： 1、为尊重中小投资者利益，提高中小投资者对公司股东大会决议事项的参 与度，本次股东大会对中小投资者进行单独计票，中小投资者是指除上市公司董 事、监事、高级管理人员以及单独或者合计持有公司5%以上股份的股东以外的 其他股东； 2、本次股东大会不存在增加、变更、否决议案的情况； 证券代码：300294 证券简称：博雅生物 公告编号：2025-067 华润博雅生物制药集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 3、本次股东大会不存在变更前次股东大会决议的情况； 4、本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 华润博雅生物制药集团股份有限公司(以下简称公司)2025 年第一次临时股 东大会通知已于 2025 年 8 月 23 日在中国证券监督管理委员会指定信息披露网站 巨潮资讯网（www.cninfo.com.cn）以公告方式发出。会议于 2025 年 9 月 12 日在 江西省抚州市高新技术产业开发区惠泉路 333 号公司会议室以现场与网络投票 相结合的方式召开。本次股东 ...

Group 1 - The company, Boya Bio-Pharmaceutical (300294.SZ), primarily engages in the research, development, production, and sales of blood products [1] - The company does not involve itself in the field of traditional Chinese medicine [1]

Investment Rating - The report maintains a "Buy" rating for the company [6][13] Core Views - The company is steadily increasing its plasma collection volume and expanding the number of plasma stations through both organic growth and acquisitions. The introduction of new products, particularly the 10% immunoglobulin, is expected to contribute to revenue growth [2][13] - The financial forecast indicates a projected revenue increase from 1,943 million yuan in 2025 to 2,466 million yuan by 2027, reflecting a compound annual growth rate (CAGR) of approximately 12% [4][14] - The net profit attributable to shareholders is expected to rise from 461 million yuan in 2025 to 666 million yuan in 2027, with a corresponding increase in earnings per share (EPS) from 0.91 yuan to 1.32 yuan [4][14] Financial Summary - Total revenue for 2023 is reported at 2,652 million yuan, with a forecasted decline to 1,735 million yuan in 2024, followed by a recovery to 1,943 million yuan in 2025 [4] - The net profit attributable to shareholders is projected to decrease from 237 million yuan in 2023 to 397 million yuan in 2024, before increasing to 461 million yuan in 2025 [4] - The company’s return on equity (ROE) is expected to improve from 3.2% in 2023 to 7.5% by 2027 [4][14] Market Data - The current stock price is 25.77 yuan, with a target price set at 30.18 yuan, indicating a potential upside [6][7] - The company has a market capitalization of approximately 12,994 million yuan and a price-to-earnings (P/E) ratio of 54.72 for 2023, which is expected to decrease to 19.51 by 2027 [4][7] Industry Context - The company operates within the pharmaceutical and essential consumer goods sector, focusing on blood products [5]

Core Viewpoint - The company has signed a contract to transfer 80% of its stake in Jiangxi Boya Xinha Pharmaceutical Co., Ltd. to Fuzhou High-tech Zone Financial Investment Group Co., Ltd. [1] Group 1 - The transfer was formalized through the "Shanghai Property Rights Transaction Contract" [1] - As of September 8, 2025, the relevant industrial and commercial change registration procedures have been completed [1] - After the transfer, the company will hold a 10.6869% stake in Boya Xinha, while its wholly-owned subsidiary, Jiangxi Boya Pharmaceutical Investment Co., Ltd., will hold a 9.3131% stake [1] Group 2 - Following the completion of the transfer, Boya Xinha will no longer be included in the company's consolidated financial statements [1]

2025 年 9 月 8 日，公司收到博雅欣和转来的《公司变更通知书》，博雅欣 和完成了上述股权转让的相关工商变更登记手续。上述股权转让后，公司直接持 有博雅欣和 10.6869%股权，全资子公司江西博雅医药投资有限公司持有博雅欣 和 9.3131%股权，博雅欣和不再纳入公司的合并报表范围。 关于转让江西博雅欣和制药有限公司 80%股权事项进展 暨完成工商变更的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：300294 证券简称：博雅生物 公告编号：2025-065 华润博雅生物制药集团股份有限公司（以下简称公司）于 2025 年 7 月 21 日披露了《关于挂牌转让江西博雅欣和制药有限公司 80%股权进展暨交易结果的 公告》（公告编号：2025-054），公司与抚州高新区财投集团有限公司签署了《上 海市产权交易合同》，公司将江西博雅欣和制药有限公司（以下简称博雅欣和） 80%股权转让给抚州高新区财投集团有限公司。 华润博雅生物制药集团股份有限公司 华润博雅生物制药集团股份有限公司董事会 2025 年 9 月 9 日 ...

Group 1: Key Recommendations - Boya Bio (300294) shows steady growth in plasma collection, with high-concentration immunoglobulin approved for market launch. The company reported a revenue of 1.008 billion yuan in H1 2025, a year-on-year increase of 12.51%, while net profit decreased by 28.68% to 225 million yuan [5][6][8] - The RMB appreciation is driven by market forces rather than policy interventions, with the recent strengthening attributed to a weak dollar and increased attractiveness of RMB assets [9][10][11] - Anjuke Food (603345) faces short-term profit pressure but is expected to see demand improvement. The company achieved a revenue of 7.604 billion yuan in H1 2025, a slight increase of 0.80%, while net profit fell by 15.79% [14][15][19] Group 2: Company Performance Insights - Boya Bio's blood product business generated 852 million yuan in revenue in H1 2025, a year-on-year increase of 7.90%. The company is focusing on its core business after divesting from non-core assets [6][7] - Anjuke Food's core products showed mixed performance, with revenue from prepared foods declining by 1.94% in H1 2025, while dish products increased by 9.40% [16][18] - The gross margin for Anjuke Food decreased to 20.52% in H1 2025, primarily due to rising raw material costs and increased competition [18] Group 3: Market Trends and Economic Indicators - The A-share market is experiencing a downward trend, with the Shanghai Composite Index closing at 3813 points, down 1.16%. The market sentiment remains low, with significant net outflows of large funds [22][24] - The RMB's recent appreciation has not been affected by foreign capital outflows from the bond market, indicating a strategic shift by foreign investors towards equities [12][13] - The food industry is facing challenges from increased competition and rising raw material prices, impacting profit margins across companies [19][20]